Get The Free Sample Complete
SWOT & PESTLE Analysis Report
This report is shared in order to give you an idea of what the complete SWOT & PESTLE analysis report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals, at such affordable pricing.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get Your Free Summary Copy of the
SWOT & PESTLE Analysis Report
Get the summary SWOT & PESTLE.com report delivered straight to your email inbox for free. Our insightful and holistic reports have helped corporates, academia and researchers take their research forward. You also agree to receive email updates from us on our new reports and solutions.

Amgen SWOT & PESTLE Analysis

ID : 52275253| Sep 2020| 15 pages

COMPANY PROFILE -Amgen

Business Sector :Pharmaceutical

Operating Geography :United States, North America, Global

About Amgen :

Amgen Inc. is an American biopharmaceutical MNC founded in 1980. It was formerly known as Applied Molecular Genetics (1980-1983) till its initial public offering in 1983. Its headquarters are located in Thousand Oaks, California, US. Amgen’s products caters to specific niche medical needs and endeavors to accomplish solutions which improve health and transform people’s lives. This American Biotech pioneer has expanded to become one of the world’s leading independent biotechnology firms, has touched the lives of millions of patients across the world and researching on a string of disruptive medicines with transformative potential. It has its presence in approximately 100 countries with almost 21,000 staff members as of early 2019.
Amgen’s mission statement reads “To Serve Patients”. Amgen’s USP lies in being one of the world’s largest pharmaceutical companies in terms of revenue and has a market cap of over $120 billion.

Amgen Revenue :


US $23.70 billion – (FY ended 31st Dec 2018) (year-on year decrease of 4%)
US $22.80 billion – (FY ended 31st Dec 2017) (year-on year decrease of -1%)
US $22.99 billion – (FY ended 31st Dec 2016)

Competitive Analysis of Amgen

SWOT
PESTLE
The SWOT analysis for Amgen is presented below:
Strengths
Weaknesses
1. Regularly innovating and developing new products
2. Biology-first approach
3. World’s largest independent biotechnology firm
4. Robust economic earnings
5. Well positioned oncology/hematology portfolio
1. Huge Cost incurred for research and development of new products
2. Battling flat sales growth
Opportunities
Threats
1. Potential long term catalysts – biosimilars
2. There are still many life threatening diseases with no cure which can be developed
3. Expansion global commercial reach to developing countries
1. Sales affected by third party payer like government and US legislation
2. Protection provided by patents is limited and can be challenged by competitors
3. Competition from biosimilars and pricing power denting market profitability
SWOT & PESTLE (combined)
Complete Report
USD 12.53
*
  • with PayPal
  • with Debit/Credit card
Great quality, Affordable pricing.
Safe and secure payments
On purchase, the report will reach your email inbox within minutes. At rare times, a slight delay not exceeding 4 hours might be caused.

Detailed SWOT Analysis of Amgen

 

Strength

This section is available only in the 'Complete Report' on purchase.

Weakness

This section is available only in the 'Complete Report' on purchase.

Opportunity

1. Potential long term catalysts – biosimilars: Amgen shares in 2019 are likely to have a big impact owing to the results of its biosimilar investments. Two new products, Kanjiti and Amgevita were launched in Europe in 2018 with 8 more launches expected soon. Strong growth and a revenue boost are thus expected. AMGEVITA is a close copy of AbbVie’s HUMIRA and KANJINTI is similar to Roche’s Herceptin. Amgen hopes to reap success in the highly competitive biosimilar market, basing its hopes upon the high-value options that they present to patients. The company also seeks to opportunize on its precision biologics manufacturing and launch a number of other biosimilars in the upcoming years.

2. There are still many life threatening diseases with no cure which can be developed: There are many diseases for which cure is not available. Various kinds of diseases are spreading due to human deeds which includes population increase, pollution etc. Those diseases include Asthma, Diabetes, Ebola virus, HIV – for these diseases, no any cure is available so that the patient can be 100% safe. Although, it is possible that some of them can be stopped/paused in their preliminary stage. Being one of top pharmaceutical company Amgen can surely look for opportunities by developing the live saving medicines.

3. Expansion global commercial reach to developing countries: Currently Amgen is having business mostly in North America and South America, Europe and China when we talk about bulk. Amgen needs to upgrade its supply system in order to successfully improve the company’s global commercial reach. The company has increased its global presence from 50 countries in 2011 to its current 100 countries presence. The company is thus playing an important part in improving world healthcare. The company also recently entered the world’s second largest pharmaceutical market, China with the relaunch of Repatha. Amgen Astellas BioPharma joint venture in Japan, the world’s third largest pharma market, also recently gained two new product approvals – BLINCYTO and EVENITY for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia and for the treatment of osteoporosis in patients at high risk of fracture respectively. But still Asian African countries are not yet tapped. This can be seen as plethora of opportunity as these two continents have larger population and will require more cure for diseases than those places where population is low. So, seeing this, Amgen needs to establish its branches or subsidiaries in these countries. This will help in getting better margins as well as catering to more number of populations in these developing nations.

Threat

This section is available only in the 'Complete Report' on purchase.

SWOT & PESTLE (combined)
Complete Report
USD 12.53
*
  • with PayPal
  • with Debit/Credit card
Great quality, Affordable pricing.
Safe and secure payments
On purchase, the report will reach your email inbox within minutes. At rare times, a slight delay not exceeding 4 hours might be caused.

Check Out Analysis of Other Relevant Companies

TABLE OF CONTENTS
DELIVERY AND FORMAT
WHY CHOOSE US?
References used in Amgen Analysis Report

1. Amgen Annual Report - https://investors.amgen.com/static-files/e3bd5ffc-957d-4dac-a8b4-5ed9a9a34e94

2. Amgen Q1 financial results 2019 - https://www.amgen.com/media/news-releases/2019/04/amgen-reports-first-quarter-2019-financial-results/

3. Amgen Company Website - https://www.amgen.com/

4. Amgen CSR Report 2018 - https://www.amgen.com/~/media/amgen/full/www-amgen-com/downloads/responsibility-report/amgen-2018-responsibility-highlights-report.ashx

5. Amgen About Us - https://www.amgen.com/about/

The detailed complete set of references are available on request in the 'Complete report' on purchase.

How to Reference This Page?

You can use the following in your reference section in order to give credit to the source. For different referencing styles and detailed guidelines, please click here.

Amgen SWOT & PESTLE Analysis - SWOT & PESTLE.COM

SWOT & PESTLE.com (2020). Amgen SWOT & PESTLE Analysis - SWOT & PESTLE.com. [online] Available at: https://www.swotandpestle.com/amgen/ [Accessed 24 Nov, 2020].

In-text: (SWOT & PESTLE.com, 2020)

Copyrights and Disclaimer

Amgen SWOT and PESTLE analysis has been conducted by Harsh Vaibhav and reviewed by senior analysts from Barakaat Consulting.

Copyright of Amgen SWOT and PESTLE Analysis is the property of Barakaat Consulting. Please refer to the Terms and Conditions for usage guidelines.

The text on www.swotandpestle.com are the property of Barakaat Consulting. While every attempt has been made to ensure completeness, accuracy and reliability of the analysis, Barakaat Consulting and its associate websites cannot be held responsible for omissions or errors in our pages or any links on any of our pages. Analyses published by us above may not totally reflect the company's opinions, reader's discretion is advised. Users have the right to choose the products that suits them the most.

You might also like to check out :
Amgen SWOT & PESTLE Analysis
Price : USD 12.53